These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 29182993)

  • 1. Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod.
    Fragoso YD; Spelman T; Boz C; Alroughani R; Lugaresi A; Vucic S; Butzkueven H; Terzi M; Havrdova E; Horakova D; Granella F; Olascoaga J; Sánchez-Menoyo JL; Pucci E; Barnett M; Brooks JBB; Haartsen J;
    Mult Scler Relat Disord; 2018 Jan; 19():105-108. PubMed ID: 29182993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline Differences in Minor Lymphocyte Subpopulations may Predict Response to Fingolimod in Relapsing-Remitting Multiple Sclerosis Patients.
    Teniente-Serra A; Hervás JV; Quirant-Sánchez B; Mansilla MJ; Grau-López L; Ramo-Tello C; Martínez-Cáceres EM
    CNS Neurosci Ther; 2016 Jul; 22(7):584-92. PubMed ID: 27080413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
    Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationships of total leukocyte, neutrophil and lymphocyte levels with the menstrual cycle in patients receiving fingolimod treatment.
    Ekmekyapar T; Ozcan C; Ciftci O
    Eur Rev Med Pharmacol Sci; 2021 Jan; 25(1):447-454. PubMed ID: 33506935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term results from a phase 2 extension study of fingolimod at high and approved dose in relapsing multiple sclerosis.
    Montalban X; Comi G; Antel J; O'Connor P; de Vera A; Cremer M; Sfikas N; von Rosenstiel P; Kappos L
    J Neurol; 2015 Dec; 262(12):2627-34. PubMed ID: 26338810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Newly produced T and B lymphocytes and T-cell receptor repertoire diversity are reduced in peripheral blood of fingolimod-treated multiple sclerosis patients.
    Chiarini M; Sottini A; Bertoli D; Serana F; Caimi L; Rasia S; Capra R; Imberti L
    Mult Scler; 2015 May; 21(6):726-34. PubMed ID: 25392322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of reduced fingolimod dosage treatment.
    Yamout BI; Zeineddine MM; Sawaya RA; Khoury SJ
    J Neuroimmunol; 2015 Aug; 285():13-5. PubMed ID: 26198913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of fingolimod on CD4+ T cell subset and cytokine profile of relapsing remitting multiple sclerosis patients.
    Kürtüncü M; Yılmaz V; Akçay Hİ; Türkoğlu R; Altunrende B; Çınar SA; Ulusoy C; Gündüz T; İçöz S; Kasap M; Çalışkan Z; Ötünç G; Eraksoy M; Tüzün E
    J Neuroimmunol; 2019 Dec; 337():577065. PubMed ID: 31526917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fingolimod Therapy in Multiple Sclerosis Leads to the Enrichment of a Subpopulation of Aged NK Cells.
    Schwichtenberg SC; Wisgalla A; Schroeder-Castagno M; Alvarez-González C; Schlickeiser S; Siebert N; Bellmann-Strobl J; Wernecke KD; Paul F; Dörr J; Infante-Duarte C
    Neurotherapeutics; 2021 Jul; 18(3):1783-1797. PubMed ID: 34244929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of relapsing-remitting multiple sclerosis with fingolimod in routine clinical practice].
    Alcala-Vicente C; Perez-Miralles FC; Gascon-Gimenez F; Bosca-Blasco I; Navarre-Gimeno A; Coret-Ferrer F; Casanova-Estruch B
    Rev Neurol; 2017 May; 64(10):445-453. PubMed ID: 28497440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early initiation of fingolimod reduces the rate of severe relapses over the long term: Post hoc analysis from the FREEDOMS, FREEDOMS II, and TRANSFORMS studies.
    Haas J; Jeffery D; Silva D; Meier DP; Meinert R; Cohen J; Hartung HP
    Mult Scler Relat Disord; 2019 Nov; 36():101335. PubMed ID: 31557679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fingolimod and Dimethyl-Fumarate-Derived Lymphopenia is not Associated with Short-Term Treatment Response and Risk of Infections in a Real-Life MS Population.
    Boffa G; Bruschi N; Cellerino M; Lapucci C; Novi G; Sbragia E; Capello E; Uccelli A; Inglese M
    CNS Drugs; 2020 Apr; 34(4):425-432. PubMed ID: 32193826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.
    Kalincik T; Horakova D; Spelman T; Jokubaitis V; Trojano M; Lugaresi A; Izquierdo G; Rozsa C; Grammond P; Alroughani R; Duquette P; Girard M; Pucci E; Lechner-Scott J; Slee M; Fernandez-Bolanos R; Grand'Maison F; Hupperts R; Verheul F; Hodgkinson S; Oreja-Guevara C; Spitaleri D; Barnett M; Terzi M; Bergamaschi R; McCombe P; Sanchez-Menoyo J; Simo M; Csepany T; Rum G; Boz C; Havrdova E; Butzkueven H;
    Ann Neurol; 2015 Mar; 77(3):425-35. PubMed ID: 25546031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased multiple sclerosis disease activity in patients transitioned from fingolimod to dimethyl fumarate: a case series.
    Delgado S; Hernandez J; Tornes L; Rammohan K
    BMC Neurol; 2021 Feb; 21(1):48. PubMed ID: 33530945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term efficacy and safety of fingolimod in Japanese patients with relapsing multiple sclerosis: 3-year results of the phase 2 extension study.
    Saida T; Itoyama Y; Kikuchi S; Hao Q; Kurosawa T; Ueda K; Auberson LZ; Tsumiyama I; Nagato K; Kira JI
    BMC Neurol; 2017 Jan; 17(1):17. PubMed ID: 28129749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Warts and all: Fingolimod and unusual HPV-associated lesions.
    Triplett J; Kermode AG; Corbett A; Reddel SW
    Mult Scler; 2019 Oct; 25(11):1547-1550. PubMed ID: 30427266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fingolimod does not impair T-cell release from the thymus and beneficially affects Treg function in patients with multiple sclerosis.
    Haas J; Schwarz A; Korporal-Kunke M; Jarius S; Wiendl H; Kieseier BC; Wildemann B
    Mult Scler; 2015 Oct; 21(12):1521-32. PubMed ID: 25583847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Five-year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis.
    Izquierdo G; O'Connor P; Montalban X; von Rosenstiel P; Cremer M; de Vera A; Sfikas N; Francis G; Radue EW; Kappos L
    Mult Scler; 2014 Jun; 20(7):877-81. PubMed ID: 24293455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphocyte subsets as biomarkers of therapeutic response in Fingolimod treated Relapsing Multiple Sclerosis patients.
    Paolicelli D; Manni A; D'Onghia M; Direnzo V; Iaffaldano P; Zoccolella S; Di Lecce V; Tortorella C; Specchia G; Trojano M
    J Neuroimmunol; 2017 Feb; 303():75-80. PubMed ID: 28043652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of disability progression in fingolimod-treated patients.
    Lattanzi S; Danni M; Cerqua R; Taffi R; Provinciali L; Silvestrini M
    J Neurol Sci; 2015 Nov; 358(1-2):432-4. PubMed ID: 26362335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.